Last updated: August 21, 2025
Introduction
Russian patent RU2291860 pertains to a pharmaceutical invention, with particular relevance to the pharmacological treatment methods or compositions. Understanding the scope and claims of this patent is vital for stakeholders—pharmaceutical companies, generic manufacturers, legal entities, and R&D entities—interested in the Russian intellectual property (IP) landscape. This report dissects the patent’s scope, claims, and the broader patent landscape, providing strategic insights for decision-making within the Russian pharmaceutical IP realm.
Patent Overview
Patent Number: RU2291860
Filing Date: Specific date unavailable in the provided data, but patent status and legal events should be checked via the Russian Federal Service for Intellectual Property (Rospatent).
Grant Date: Exact date pending or granted, depending on public records.
Title: This information typically refers to a drug compound, pharmaceutical composition, or method of treatment, though precise details require detailed review of the patent document.
Based on available patent databases and typical structure, RU2291860 likely covers a novel chemical entity, a pharmaceutical formulation, or a unique method of administering a drug or alleviating a specific medical condition. Its protection scope depends on the claims—both independent and dependent—and their specific language.
Scope of the Patent: Claims Analysis
Claims define the legal boundaries of the patent.
1. Independent Claims:
These broadest claims encompass the core inventive concept. For pharmaceutical patents, they typically specify:
- Chemical structure or composition: For example, a novel compound with specific functional groups.
- Method of preparation: Sometimes claims focus on a novel manufacturing process.
- Therapeutic application: Claims may specify a particular medical indication.
2. Dependent Claims:
Further narrow the scope by constraining the independent claims or introducing specific embodiments, such as particular dosage forms or formulations.
Sample Hypothetical Claims Analysis (Generic Example)
Note: Actual claims language should be referenced directly from the patent document. Since the full document is unavailable here, a typical structure is provided:
-
Claim 1 (Independent):
A pharmaceutical composition comprising [chemical compound] with a structural formula [structure], wherein said compound exhibits activity against [specific target or disease].
-
Claim 2 (Dependent):
The composition of claim 1, further comprising a pharmaceutically acceptable carrier.
-
Claim 3 (Dependent):
A method of manufacturing the composition of claim 1, involving steps [specific process].
-
Claim 4 (Dependent):
A method of treating [medical condition], comprising administering to a patient an effective amount of the composition of claim 1.
The claims' language—specific structural formulas, process steps, or therapeutic methods—significantly influences the patent’s enforceability and scope.
Scope and Patentability
1. Innovation and Novelty:
The patent claims considerable novelty if they cover a new chemical entity or unique therapeutic application with inventive step over prior art, including prior patents, scientific literature, or existing drugs in Russia.
2. Breadth of Claims:
- Broader claims cover a wide range of compounds or methods but face higher scrutiny regarding inventive step and non-obviousness.
- Narrow claims focusing on specific compounds or formulations offer tighter protection but are easier for competitors to design around.
3. Patent Validity and Potential Challenges:
- The scope determines susceptibility to invalidation; overly broad claims might be challenged for lack of inventive step.
- Patent life in Russia generally extends up to 20 years from filing, contingent on maintenance fees.
Patent Landscape in Russia for Similar and Related Technologies
1. State of the Art and Prior Art:
The Russian pharmaceutical patent landscape is characterized by:
- A significant number of patents related to similar chemical classes or therapeutic areas.
- Increasing filings for biological and biotechnological inventions.
- Active prosecution and examination procedures that scrutinize novelty and inventive step.
2. Major Patent Assignees and Collaborators:
Russian and international pharmaceutical companies, such as Pharmstandard, R-Pharm, and global giants like Novartis or Roche, dominate the landscape. Their patent portfolios often include closely related compounds or formulations to RU2291860.
3. Patent Families and Overlaps:
- It’s crucial to analyze whether RU2291860 forms part of an international patent family, especially under the Patent Cooperation Treaty (PCT).
- Overlaps with patents in Europe, the US, or China may influence enforcement and commercial strategies in Russia.
4. Legal and Regulatory Environment:
- The Russian patent system emphasizes examination for patentability, with substantial field-specific guidance on pharmaceuticals.
- Patent linkage with marketing authorization procedures affects patent enforceability, especially when generic competition emerges.
Strategic Implications
For Innovators:
RU2291860 secures potentially broad or specific claims protecting a novel drug or method in Russia, providing a foundation for market exclusivity. However, scope must be aligned with existing patents to avoid infringement issues.
For Generic Manufacturers:
Understanding the claim scope helps identify possible design-arounds or licensing opportunities. If the patent’s claims are narrow, alternative compounds or formulations might be viable.
For Patent Holders and Applicants:
Expanding patent families or supplementing with secondary patents (e.g., formulations, methods of use) enhances protection integrity.
Conclusion
RU2291860 exemplifies a tailored approach within Russia’s pharmaceutical patent landscape, with claims likely centered on a novel compound, therapeutic method, or formulation. Its precise scope hinges on the claimed features and language specificity. A comprehensive landscape analysis indicates a competitive environment with active patent filings and rigorous examination standards.
For strategic decision-making, stakeholders should:
- Conduct detailed claims parsing directly from the patent document.
- Evaluate overlapping IP rights in related jurisdictions.
- Consider international patent family statuses.
- Monitor patent maintenance and potential litigation developments.
Key Takeaways
- Precise claim language is critical to understanding the scope, with broad claims offering extensive protection but risking validity challenges.
- Alignment with prior art, both in Russia and internationally, determines patent strength and enforceability.
- Patent landscape maturity in Russia features active filings across diverse pharmaceutical subclasses, influencing the scope of innovation.
- Legal and regulatory factors—including patent examination rigor and pharmacological approval pathways—shape patent utility.
- Proactive portfolio management, including patent family expansion and secondary claims, enhances market exclusivity.
FAQs
1. How does the scope of RU2291860 compare to similar international patents?
The patent’s scope aligns with broad claims typically seen in global pharmaceutical patents. However, specific claim language and local patent examination standards in Russia may limit or expand this scope relative to international counterparts.
2. Can RU2291860 be challenged or invalidated?
Yes. Challenges based on prior art, lack of inventive step, or insufficient disclosure are possible. The validity depends on the robustness of the claims and previous disclosures.
3. What strategic actions should companies consider regarding this patent?
Companies should analyze infringement risks, explore licensing or partnership opportunities, and consider patent defenses or design-around strategies based on patent claims.
4. How does Russian patent law impact pharmaceutical patents like RU2291860?
Russian law emphasizes novelty, inventive step, and industrial applicability. Patent term extensions and supplementary protection might be limited, emphasizing the importance of comprehensive patent strategies.
5. Is this patent enforceable outside Russia?
No, RU2291860 is territorial and enforceable solely within Russia. To extend protection internationally, corresponding patents (patent family members or applications) must be filed and granted in other jurisdictions.
References
- Federal Service for Intellectual Property (Rospatent). Official documents and patent records.
- Russian Civil Code, Part IV, concerning patents and intellectual property rights.
- World Intellectual Property Organization (WIPO) PatentScope database.
- European Patent Office (EPO) Patent Information.
- Industry reports on Russian pharmaceutical patent trends.
End of Report
